544678-85-5

Basic information

• Product Name: MMP-13 Inhibitor
• Synonyms: MMP-13 Inhibitor;N4,N6-Bis(4-fluoro-3-Methylbenzyl)pyriMidine-4,6-dicarboxaMide;N,N'-Bis[(4-fluoro-3-methylphenyl)methyl]-4,6-pyrimidinedicarboxamide
• CAS NO: 544678-85-5
• Molecular Formula: C₂₂H₂₀F₂N₄O₂
• Molecular Weight: 410.4166064
• EINECS: -0
• Mol File: 544678-85-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 684.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.286±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: ≤0.5mg/ml in ethanol;2mg/ml in DMSO;2mg/ml in dimethyl formamide
• PKA: 11.79±0.46(Predicted)
• CAS DataBase Reference: MMP-13 Inhibitor(CAS DataBase Reference)
• NIST Chemistry Reference: MMP-13 Inhibitor(544678-85-5)
• EPA Substance Registry System: MMP-13 Inhibitor(544678-85-5)

Safety Data

• Hazardous Substances Data: 544678-85-5(Hazardous Substances Data)

Usage

Description

MMP-13 Inhibitor is a pyrimidine dicarboxamide that specifically inhibits matrix metalloproteinase-13 (MMP-13, also known as collagenase-3) with high specificity and potency, as demonstrated by its IC50 value of 8 nM. This inhibitor targets unique pockets of MMP-13, distinguishing it from other matrix metalloproteinases. It plays a crucial role in blocking osterix-dependent calcification of matrices in limb bud cells during the process of endochondral ossification. MMP-13 Inhibitor is characterized by its white crystalline appearance.

Uses

Used in Pharmaceutical Industry:
MMP-13 Inhibitor is used as a therapeutic agent for the treatment of various diseases characterized by the overexpression or abnormal activity of MMP-13. Its high specificity and potency make it a valuable candidate for the development of targeted drugs to address conditions such as arthritis, tumor invasion, and metastasis.
Used in Research Applications:
MMP-13 Inhibitor serves as a valuable research tool for studying the role of MMP-13 in various biological processes, including tissue remodeling, wound healing, and the pathogenesis of diseases. By inhibiting MMP-13, researchers can gain insights into the molecular mechanisms underlying these processes and identify potential therapeutic targets.
Used in Drug Development:
MMP-13 Inhibitor is utilized in the development of novel drugs targeting MMP-13 for the treatment of diseases with a strong association to MMP-13 activity. Its specificity and potency make it an attractive starting point for designing and optimizing new inhibitors with improved pharmacological properties, such as better bioavailability, reduced side effects, and enhanced efficacy.
Used in Diagnostic Applications:
MMP-13 Inhibitor can be employed in the development of diagnostic tools to detect and monitor the activity of MMP-13 in patients. By measuring the levels of MMP-13 activity, healthcare professionals can assess the severity of a disease, monitor the progression of the condition, and evaluate the effectiveness of treatment strategies.

in vitro

mmp-13 inhibitor was previously synthesized as a pyrimidine dicarboxamide that could inhibit the matrix metalloproteinase-13 (mmp-13) with the ic50 of 8 nm. moreover, mmp-13 inhibitor was found to be able to bind to mmp pockets that are unique to mmp-13 rather than the catalytic zinc, and therefore was specific for mmp-13 over other mmps. in addition, during endochondral ossification, mmp-13 inhibitor could also block osterix-dependent calcification of matrices in limb bud cells [1, 2, 3].

IC 50

8 nm

references

1. carrascal, n.a. and rizzo, r.c. calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with mmp-13. bioorg.med.chem.lett. 19(1), (2009).2. engel, c.k.,pirard, b.,schimanski, s., et al. structural basis for the highly selective inhibition of mmp-13. chem.biol. 12(2), 181-189 (2005).3. nishimura, r.,wakabayashi, m.,hata, k., et al. osterix regulates calcification and degradation of chondrogenic matrices through matrix metalloproteinase 13 (mmp13) expression in association with transcription factor runx2 during endochondral ossification. j.biol.chem. 287(40), 33179-33190 (2012).

Upstream product

• 261951-68-2 4-fluoro-3-methylbenzylamine 
• 6345-43-3 pyrimidine-4,6-dicarboxylic acid dimethyl ester 

Relevant articles and documents

Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis

Osteoarthritis (OA) is a chronic disorder that causes damage to the cartilage and surrounding tissues and is characterized by pain, stiffness, and loss of function. Current treatments for OA primarily involve providing only relief of symptoms but does not

PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES AND PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES AND THE USE THEREOF FOR SELECTIVELY INHIBITING COLLAGENASES

Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides of formula I. These compounds are found to possess the property of selectively inhibiting collagenase (MMP). They may therefore be useful in prophylaxis and therapy of diseases whose course involves an increased activity of matrix metalloproteinase 13.